GreenLight XPS 180-W Laser Vaporization of Prostate in High-Risk Elderly Patients: A Single-Center Experience

To evaluate the safety and efficacy of GreenLight XPS 180-W laser photoselective vaporization of the prostate (PVP) in high-risk elderly patients with benign prostatic hyperplasia. This retrospective study included 150 elderly patients with enlarged prostate glands (>40 mL) receiving 180-W photoselective vaporization at our department between January 2016 and October 2018. All patients were of advanced age (>80 years) and included those at higher risk of bleeding and cardiopulmonary disease. Perioperative data were collected and analyzed. All operations were completed uneventfully without conversion to open surgery, and nobody died due to postoperative complications. The mean preoperative prostate volume was 65 ± 12.5 mL, mean operative time was 63 ± 12.5 min, mean laser working time was 51 ± 9.2 min, and mean catheterization time was 2.7 ± 1.8 days. There were significant improvements in International Prostate Symptom Scores, quality of life, maximum flow rate, and postvoid residual volume compared with preoperative values. Intraoperative as well as short- and long-term postoperative complication rates were 0.7%, 29.8%, and 13.3%, respectively. Three patients required rehospitalization for postoperative complications, one needed reoperation, and the others recovered after conservative treatment. PVP with a GreenLight XPS 180-W laser in high-risk elderly patients is safe and feasible. It provides a dramatic improvement in both short- and long-term functional outcomes and deserves promotion.